Alembic Pharmaceuticals has received the final USFDA approval for Abbreviated New Drug Application (ANDA) of anti-bacterial Doxycycline capsules USP 75 mg and 100 mg. The approved drug is therapeutically equivalent to a reference listed drug product Monodox capsules, 75 mg and 100 mg of Aqua Pharmaceuticals. The drug is used in the treatment and prevention of infections that are proved or strongly suspected to be caused by bacteria. According to industry data, Doxycycline capsules had an estimated market size of $30 million. The company now has 62 ANDA approvals from the US FDA.
Company Profile : Alembic Pharmaceuticals Ltd
Leave a Reply